Know Cancer

or
forgot password

Gene Expression Profiling and Immunological Mechanism Affects the Response of Malignant Cavity Effusion Towards DC-CIK Immunotherapy


N/A
18 Years
80 Years
Open (Enrolling)
Both
Malignant Tumor

Thank you

Trial Information

Gene Expression Profiling and Immunological Mechanism Affects the Response of Malignant Cavity Effusion Towards DC-CIK Immunotherapy


1. The patients with malignant cavity effusion are treated with dendritic cells (DC) plus
cytokine induced killer cells (CIK) locally.

2. Malignant cavity effusion from cancer patients is obtained through puncture and is
centrifugalized to get supernatant fluid and enrich cancer cells before and after the
therapy.

3. The enriched cancer cells which are flash frozen, as well as the supernatant, are
stored at -80°C until processing.

4. The T-Cell Receptor/B-Cell Receptor gene expression in cavity effusion is detected by
micro-array to explore the mechanism that DC-CIK immunotherapy controls the malignant
cavity effusion.

5. Statistical analysis is performed using unsupervised hierarchical cluster.


Inclusion Criteria:



1. Histologically confirmed with malignant tumor and malignant cavity effusion.

2. An Eastern Cooperative Oncology Group（ECOG）performance status of 0-2.

3. Normal cardiac, hepatic, renal and bone marrow functions.

4. Life expectancy >3 months.

5. Not receive other anti-tumor treatment.

6. Not receive chemotherapy in pleural and abdominal cavity.

Exclusion Criteria:

1. Previous history of other malignancies.

2. Serious or uncontrolled concurrent medical illness.

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Immunotherapy response

Outcome Description:

T-Cell Receptor and B-Cell Receptor gene expression profiling and the change of cytokines, lymphocytes subpopulation before and after DC-CIK infusion

Outcome Time Frame:

1 month

Safety Issue:

No

Principal Investigator

Jun Ren, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Capital Medical University Cancer Center /Beijing Shijitan Hospital

Authority:

China: Ethics Committee

Study ID:

GIMCEI

NCT ID:

NCT01884168

Start Date:

March 2013

Completion Date:

May 2015

Related Keywords:

  • Malignant Tumor
  • Neoplasms

Name

Location